Abstract:Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, and lenvatinib is a multi-kinase inhibitor approved by the FDA as a first-line drug for advanced HCC since 2018. Lenvatinib demonstrated antitumor activity with a higher objective response rate, longer progression-free survival, and time to progression in a non-inferiority trial compared with sorafenib. However, the clinical benefits of lenvatinib remain limited as acquired resistance to lenvatinib during HCC treatment is inevitable. This highlights the need to understand the molecular mechanisms of lenvatinib resistance and to explore new therapeutic approaches to overcome this resistance. Tumor lineage plasticity, a recognized hallmark of cancer, is a phenomenon in which tumor cells dedifferentiate into a more stemness state to attain cellular plasticity, enabling them to evade targeted therapeutic interventions. However, the mechanism by which cellular plasticity contributes to lenvatinib resistance remains elusive. In this study, we employed proteomic mass spectrometry to investigate altered proteins in two pairs of parental lenvatinib-sensitive and their corresponding trained lenvatinib-resistant HCC cell lines. This analysis revealed that upregulation of enolase 2 (ENO2), a glycolytic enzyme that catalyzes the dehydration and conversion of 2-phosphoglycerate to phosphoenolpyruvate, is a critical contributor. ENO2 upregulation is frequently observed in HCC and is strongly correlated with aggressive clinical features, including poor survival, advanced tumor stage, and poor differentiation status. We further showed that ENO2 upregulation in HCC is positively correlated with stemness and hepatic progenitor marker signatures, as well as hypoxia, and subsequently demonstrated that ENO2 is regulated by hypoxia/HIF-1α, with hypoxia response element sequences located in the ENO2 promoter region. Research is underway to investigate the functional role and underlying molecular mechanisms associated with ENO2-driven lenvatinib resistance and cellular plasticity in HCC. Citation Format: Sukbum Kim, Jia-Jian Loh, Huajian Yu, Ki-Fong Man, Kai-Yu Ng, Terence Kin-Wah Lee, Clive Yik-Sham Chung, Stephanie Ma. Mass spectrometry profiling identifies ENO2 as a driver of lenvatinib resistance in hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1988.

Interference with ENO2 promotes ferroptosis and inhibits glycolysis in clear cell renal cell carcinoma by regulating Hippo‐YAP1 signaling

ENO3 Promotes Colorectal Cancer Progression by Enhancing Cell Glycolysis

ENO1 deletion potentiates ferroptosis and decreases glycolysis in colorectal cancer cells via AKT/STAT3 signaling

ENO2 Promotes Colorectal Cancer Metastasis by Interacting with the LncRNA CYTOR and Activating YAP1-Induced EMT.

Knockdown of ENO1 promotes autophagy dependent‐ferroptosis and suppresses glycolysis in breast cancer cells via the regulation of CST1

ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway

Enolase 1 Stimulates Glycolysis to Promote Chemoresistance in Gastric Cancer.

Role of ENO1 and its targeted therapy in tumors

Oncogenic Activation of YAP Signaling Sensitizes Ferroptosis of Hepatocellular Carcinoma via ALOXE3-Mediated Lipid Peroxidation Accumulation

Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway

ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism

Mediation of PKM2-dependent glycolytic and non-glycolytic pathways by ENO2 in head and neck cancer development

O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer.

Integrated Multi-Omics Analysis Identifies ENY2 As a Predictor of Recurrence and a Regulator of Telomere Maintenance in Hepatocellular Carcinoma

ACAT2 negatively modulated by FOXA2 suppresses ferroptosis to expedite the aggressive phenotypes of endometrial cancer cells

The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma

Ferroptosis-associated genes and compounds in renal cell carcinoma

Abstract 1988: Mass spectrometry profiling identifies ENO2 as a driver of lenvatinib resistance in hepatocellular carcinoma

ENO1 Promotes OSCC Migration and Invasion by Orchestrating IL-6 Secretion from Macrophages via a Positive Feedback Loop

NEK2 affects the ferroptosis sensitivity of gastric cancer cells by regulating the expression of HMOX1 through Keap1/Nrf2

ENO1 Promotes Lung Cancer Metastasis via HGFR and WNT Signaling–Driven Epithelial-to-Mesenchymal Transition